产品
编 号：F197794
分子式：C17H10F6N6O
分子量：428.29
分子式：C17H10F6N6O
分子量：428.29
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1642300-52-4
产品详情
生物活性：
Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines.
体内研究：
KPT-8602 (15 mg/kg；口服填喂法；每日给药；共 12 天) 显示出有效的抗淋巴细胞白血病活性。Animal Model:Female BALB/c mice (model with the JAK3 (M511I) mutation)
Dosage:15 mg/kg
Administration:Oral gavage; daily for 12 days
Result:Showed a marked reduction in total white blood cell (WBC) counts after 2 days of treatment compared to placebo-treated animals and the WBC counts continued to drop until they reached normal levels (<10,000 cells/μL) by day 12.
体外研究：
KPT-8602 (2-6 nM;EC50s范围在25 ~ 145 nM KPT-8602 (1 nM;。”
Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines.
体内研究：
KPT-8602 (15 mg/kg；口服填喂法；每日给药；共 12 天) 显示出有效的抗淋巴细胞白血病活性。Animal Model:Female BALB/c mice (model with the JAK3 (M511I) mutation)
Dosage:15 mg/kg
Administration:Oral gavage; daily for 12 days
Result:Showed a marked reduction in total white blood cell (WBC) counts after 2 days of treatment compared to placebo-treated animals and the WBC counts continued to drop until they reached normal levels (<10,000 cells/μL) by day 12.
体外研究：
KPT-8602 (2-6 nM;EC50s范围在25 ~ 145 nM KPT-8602 (1 nM;。”
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备